GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (FRA:TGNA) » Definitions » 3-Year ROIIC %

Transgene (FRA:TGNA) 3-Year ROIIC % : 14.26% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Transgene 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Transgene's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was 14.26%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Transgene's 3-Year ROIIC % or its related term are showing as below:

FRA:TGNA's 3-Year ROIIC % is ranked better than
67.3% of 1358 companies
in the Biotechnology industry
Industry Median: -13.43 vs FRA:TGNA: 14.26

Transgene 3-Year ROIIC % Historical Data

The historical data trend for Transgene's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene 3-Year ROIIC % Chart

Transgene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.67 72.34 -7.18 10.55 14.26

Transgene Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 10.55 - 14.26 -

Competitive Comparison of Transgene's 3-Year ROIIC %

For the Biotechnology subindustry, Transgene's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transgene's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Transgene's 3-Year ROIIC % falls into.



Transgene 3-Year ROIIC % Calculation

Transgene's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -28.675 (Dec. 2023) - -24.326 (Dec. 2020) )/( 29.039 (Dec. 2023) - 59.538 (Dec. 2020) )
=-4.349/-30.499
=14.26%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Transgene  (FRA:TGNA) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Transgene 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Transgene's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Transgene Business Description

Traded in Other Exchanges
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, FRA, 67400
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.